Nutrient response
Engages glucose-dependent nutrient signaling pathways involved in insulin response and energy balance.
RESEARCH STATUSFor research use only. Not for human consumption. Retatrutide is investigational and not FDA-approved.
Y / 001 — INVESTIGATIONAL
RETA
Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist being investigated by Eli Lilly. It is not FDA-approved and is not legally available as a medicine outside authorized clinical trials.
3RECEPTORS
338PHASE 2 PARTICIPANTS
48WEEKS STUDIED
24.2%MEAN CHANGE AT 12 MG*
PHASE 3INVESTIGATIONAL STATUS
Human trialWHAT THE PHASE 2
WHAT THE PHASE 2
TRIAL FOUND
In the 48-week randomized trial, mean weight change was dose-dependent: −8.7% at 1 mg, −17.1% in combined 4 mg groups, −22.8% in combined 8 mg groups, and −24.2% at 12 mg, versus −2.1% with placebo.
The study enrolled adults with obesity or overweight plus a weight-related condition. These findings apply to the trial population and investigational material used under clinical controls—not unverified retail products.
Read the NEJM paper ↗MECHANISM THREE SIGNALS, ONE MOLECULE
Satiety signaling
Engages pathways associated with appetite, gastric emptying, and glucose-dependent insulin secretion.
Energy metabolism
Engages glucagon-receptor pathways studied for effects on hepatic metabolism and energy expenditure.
WHAT PARTICIPANTS
REPORTED
This is safety reporting from the published trial—not customer testimonials.
Most common observations
- Gastrointestinal events were most common.
- Events were dose-related and mostly mild to moderate.
- Lower starting doses partly reduced GI effects.
- Heart rate increased dose-dependently, peaked at week 24, then declined.
- Altered or enhanced skin sensation was reported as mild to moderate.
WHAT WE STILL
DON’T KNOW.
Long-term safety and effectiveness await full phase 3 review and regulatory evaluation.
Retatrutide has not been approved by any regulatory agency.
Research labeled “for research use only” must not be represented as a consumer treatment.